Global Anxiety Disorders Market to reach $ 5.9 billion by 2017, according to a new report by Global Industry Analysts, Inc.

San Jose, CA (Vocus / PRWEB) 12 April 2011 GIA announces the release of a comprehensive global report on anxiety disorders market. The global market ...


San Jose, CA (Vocus / PRWEB) 12 April 2011

GIA announces the release of a comprehensive global report on anxiety disorders market. The global market for anxiety disorders is expected to reach $ 5.9 billion in 2017. Key factors include market growth. Increasing stress, which are the recent financial crisis, increasingly, growing incidence and prevalence of anxiety disorders, increasing aging population worldwide, the presence of significant unmet needs and the development of novel therapeutics

stress is one of the most important health issues of the 21st Century, to the extent called a global epidemic. Anxiety is a normal response to stress, the study a deal with difficult situations at work, harder for an exam, or keep focused on an important speech helps. In general, it helps to manage a. But when anxiety is excessive, irrational dread of everyday situations, it turned into a disabling disorder. Anxiety disorders are the most common mental illness that people of all ages. In recent years, the number of people who suffer from anxiety disorders performed significantly due to the global financial crisis, the rise in unemployment and increasing stress. Constantly rising aging global population is also one of the factors for the rapid increase in drug sales in the central nervous system. Major types of anxiety disorders with high prevalence include Social Anxiety Disorder, Post-Traumatic Stress Disorder, Generalized Anxiety Disorder, Panic Disorder and Obsessive Compulsive Disorder.


treated

anxiety therapy and addressing specific factors. disorder and hamper its repetition, and helps restore and maintain the normal health of those affected The first line agents for the treatment of anxiety disorders include selective serotonin reuptake inhibitors such as Lexapro (escitalopram), Paxil (paroxetine), Zoloft (sertraline) and Prozac (fluoxetine). The other drugs prescribed for GABA analogues, including new antidepressant Remeron (mirtazapine) and MAO inhibitors including Parnate (tranylcypromine) or Nardil (phenelzine), Lyrica (pregabalin) and Neurontin (gabapentin). TCAs, including imipramine, atypical antipsychotics, including quetiapine, and piperazines including hydroxyzine, are also for the treatment of anxiety. However, these drugs are known to cause various side effects and complications.

Although the foundation for the pharmacological treatment related to anxiety disorders, the response rate of serotonergic-based treatment is likely to remain below the robust level. In addition, although a number of treatment options for the treatment of anxiety disorders, about one third of patients with psychiatric disorders are still not responding to the drugs that are currently available in the market. There is a growing need for the development of drugs that provide a faster onset of action compared in contrast to the currently available drugs. The research projects. Companies partly focus on the usual kind of action, such as adjusting the noradrenaline and serotonin levels in the brain and partially performed in unique and novel mechanism Doctors are looking for new drugs for the treatment of anxiety disorders.

The existence of neurokinin (NK) receptor antagonists, along with corticotropin-releasing factor (CRF) antagonists in the anxiety disorders pipeline drew strong interest from key market participants. The NK receptor antagonist is expected to occur as promising drugs for the treatment of anxiety disorders. Furthermore, the market is expected to experience that transformation, with anti-psychotic drugs expected to change the future landscape of the anxiety disorder drug market. Manufacturers of antidepressants to target their products’ potential to increase patient when. Higher comorbidity of depression and anxiety

The U.S. is the largest regional market for anxiety disorder therapeutics provides worldwide, as stated by the new market research report on anxiety disorders. The U.S. registered the highest number of anxiety disorder cases annually. The country incurred costs of over U.S. $ 42 million per year for anxiety disorders. Account for almost one third of the total cost of mental disorders About 27% of Europeans suffer from brain disorders, with depression being the most common health problem in several EU Member States. However, Asia-Pacific predicted register the fastest growth over the analysis period, the registry. An annual growth rate of more than 5.0% during 2009-2017

Major players profiled in the report include AstraZeneca Plc., Boehringer Ingelheim, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Forest Laboratories, Inc., GlaxoSmithKline Plc, H. Lundbeck A / S, Mylan Inc., Neurocrine Biosciences, Inc., Pfizer Inc., Ratiopharm, Sanofi-Aventis, Valeant Pharmaceuticals, Watson Laboratories, among others.

The research report titled Anxiety Disorders: A Global Strategic Business Report by Global Industry Analysts Inc. announced, provides a comprehensive review of the anxiety disorders therapeutics markets, current market trends, key growth drivers, what drugs on the market, index pipeline drugs recent product approvals / launches recent industry activity, and profiles of major / niche global as well as regional market participants. The report provides annual sales estimates and projections for anxiety disorders therapeutics market for the years 2009 to 2017 for the following geographic markets – U.S., Europe, Asia-Pacific and Rest of World. In addition, a six-year is set (2003-2008) historic analysis for additional perspective available.

For more information about this comprehensive market research report, please visit http://www.strategyr.com/Anxiety_Disorders_Market_Report.asp

About Global Industry Analysts, Inc.

Global Industry Analysts, Inc., (GIA) is a reputed publisher of off-the-shelf market research. Founded in 1987, the company is globally recognized as one of the largest market research companies publishers. The company employs over 800 people worldwide and publishes more than 1200 full-scale research reports each year. In addition, the company also offers thousands of smaller research products including company reports, market trend reports and industry reports that all major industries worldwide.

Global Industry Analysts, Inc.

Phone: 408-528-9966

Fax: 408-528-9977

Email: press (at) StrategyR (dot) com

Web Site: http://www.StrategyR.com/

# # #


Leave a Reply